Justin Klee B.'s most recent trade in Amylyx Pharmaceuticals Inc was a trade of 373,295 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharma Inc | Justin B. Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 373,295 | 373,295 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Justin B. Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 248,865 | 3,583,481 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.69 per share. | 02 Feb 2026 | 15,500 | 3,363,898 | - | 14.7 | 227,618 | Common Stock |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.57 per share. | 15 Jan 2026 | 197,153 | 3,514,739 | - | 7.6 | 1,492,448 | Common Stock |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2026 | 197,153 | 2,847 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.58 per share. | 15 Jan 2026 | 136,193 | 3,378,546 | - | 13.6 | 1,849,869 | Common Stock |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.57 per share. | 15 Jan 2026 | 2,847 | 3,381,393 | - | 7.6 | 21,552 | Common Stock |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2026 | 2,847 | 0 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.89 per share. | 15 Jan 2026 | 1,995 | 3,379,398 | - | 13.9 | 27,701 | Common Stock |
| Amylyx Pharma Inc | Justin Klee B. | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.09 per share. | 06 Jan 2026 | 7,715 | 3,317,586 | - | 11.1 | 85,589 | Common Stock |